GlassScriptPhysician profile
Jeffrey Ratliff
NPI 1881918340
$41,826.86
in general payments reported to CMS, 2019-2025
8 companies · $478 in 2025
The $478 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $7,510 · 2021: $1,204 · 2022: $4,266 · 2023: $3,032 · 2024: $507 · 2025: $478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,600 · Food and Beverage: $1,384 · Education: $33.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,600.00 |
| Food and Beverage | $1,383.60 |
| Education | $33.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $25,952.48 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $7,242.66 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $4,758.74 | 2019-2023 | Nuplazid |
| Abbott Laboratories | $2,130.30 | 2019-2025 | Infinity |
| Neurocrine Biosciences, INC. | $1,250.00 | 2020-2021 | |
| Boston Scientific Corporation | $470.29 | 2023-2025 | General - Dbs, Vercise |
| Adamas Pharmaceuticals, INC. | $22.39 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Ratliff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.